Globus Medical Director Sold Shares Worth Over $3.1M

Globus Medical director Tobin James R sold 41,666 shares in two transactions on November 10, 2026, totaling $3,131,547. He no longer owns Class A Common Stock, according to an SEC filing.

Original reporting
Published Nov 12, 2026, 11:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 11:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Globus Medical Director Sold Shares Worth Over $3.1M — source image
Decision brief

The 30-second read

$GMEDBearishLow
01

Why it matters

The disclosure provides fresh insider activity data, which can influence short‑term trading sentiment.

02

Market read

Insider sales are closely watched; this $3.1M sale may prompt short‑term price adjustments.

03

What to watch

No accompanying earnings or guidance change; the sale may not reflect company fundamentals.

Relevance 5/10Novelty 5/10Timing: post‑market today

Background

Form 4 filing disclosed a director's sale of a sizable stake in Globus Medical.

Company-level read

Ticker impact

$GMEDBearishHigh confidence
Context

Director Tobin James R sold 41,666 shares for $3.13M, ending his ownership of Class A stock.

Expected impact

likely downward pressure as investors price in the insider sell

Evidence & confidence

Form 4 filing is a primary disclosure; a $3M sale by a director is material for a mid‑cap medical device company.

Market effects

May raise concerns for the broader med‑tech sector about insider confidence.

Limited to U.S. investors; no broader regional effect.

Minimal global impact beyond the company's share price.

Counterpoint

The sale could be a routine diversification move, not a negative signal.

Key entities

  • Globus Medical

    Medical device manufacturer listed on NYSE under GMED.

  • Tobin James R

    Director of Globus Medical who sold shares.

Related articles

$GMEDHighAI 8/10

Why Globus Medical (GMED) shares are plunging today

Globus Medical (GMED) shares fell 11.6% after reporting Q3 2026 revenue of $763.7M, below estimates, and lowering full-year revenue guidance to $3.09B. Adjusted EPS of $1.23 beat estimates. The company cited product launch delays and revenue recovery issues. The board authorized a $500M share repurchase program.

$GMEDHighAI 8/10

Globus Medical Inc (GMED) Q3 2026 Earnings Call Highlights: Revenue Miss, Nevro Weakness

Globus Medical (GMED) reported Q3 2026 revenue of $763.7M, missing expectations and lowering full-year guidance to $3.09B. Nevro revenue declined 25.7% YoY, and US Spine growth slowed. Despite this, free cash flow reached a record $225M, and gross margins expanded to 69.5%. The company expects 2027 growth from new products and market expansion, with mid- to high-single-digit revenue growth targeted.

$GMEDMedAI 8/10

Globus Medical Q3 Earnings Call Highlights

Globus Medical (GMED) reported Q3 earnings with GAAP net income of $141.2M and adjusted net income of $167M. The company expects a mid-single-digit revenue decline in Q4 due to delayed product launches and slower recovery at Nevro. Nevro's revenue fell 9% sequentially, but adjusted EBITDA margin improved to 19.9%. Globus plans to launch a new implantable pulse generator in 2027 and completed two small acquisitions. Operating cash flow rose 6% to $265M, and free cash flow increased 5% to $225M.

$GMEDHigh

Why Globus Medical (GMED) shares are plunging today

Globus Medical (GMED) shares fell 11.6% after Q3 2026 revenue of $763.7M missed estimates and full-year guidance was lowered to $3.09B. Adjusted EPS of $1.23 beat estimates. The company cited product launch delays and revenue recovery issues. The board authorized a $500M share repurchase program. The stock is down 17.7% YTD.

$GMEDHighAI 8/10

Why is Globus Medical stock plunging today?

Globus Medical (GMED) stock fell 12.5% to $71.26, a 52-week low, after Q3 2026 revenue missed estimates at $763.7M, down 0.7% YoY. The company cut full-year revenue guidance to $3.09B. Analysts downgraded the stock, citing weak growth outlook and insider selling. The S&P 500 and Nasdaq rose, but GMED underperformed.